Researchers have developed a technique to “reprogram” human pancreatic duct-derived cells, allowing them to replace beta cells and secrete insulin in the pancreas while avoiding genetic modification of the target cells. Researchers said that the human pancreatic duct-derived cells (HDDCs), which were reprogrammed using messenger RNA as a transcription factor, could be further developed to be used for patients with type 1 diabetes. Researchers reprogrammed HDDCs to behave like beta cells and secrete insulin within the pancreas while responding to glucose. Lysy P, et al. “RNA-based MAFA over-expression is sufficient to drive human pancreatic duct-derived cells toward a b-cell-like phenotype.” Presented at: 54th Annual European Society for Pediatric Endocrinology Meeting; Oct. 1-Oct. 3, 2015; Barcelona.